此外，据南粤清风消息，广州医药集团有限公司原党委书记、董事长李楚源涉嫌严重违纪违法，目前正接受广东省纪委监委纪律审查和监察调查。据悉，广药集团系A股上市公司白云山的母公司，李楚源原担任白云山董事长。今年7月22日，白云山曾公告称，李楚源因个人原因辞去公司第九届董事会董事长、执行董事及董事会战略发展与投资委员会主任的职务。Baiyunshan (00874) is currently down more than 5%, as of the time of publication, down 5.45% to HKD 18.38, with a turnover of HKD 29.2393 million.
According to the Futu Securities app, Baiyunshan (00874) is currently down more than 5%, as of the time of publication, down 5.45% to HKD 18.38, with a turnover of HKD 29.2393 million.
In terms of news, Baiyunshan has released its interim performance, with the group generating revenue of CNY 41.043 billion during the period, an increase of 2.68% year-on-year; net income attributable to shareholders of CNY 2.55 billion, a decrease of 9.31% year-on-year; and basic earnings per share of CNY 1.568. A cash dividend of CNY 4 will be distributed for every 10 shares.
Furthermore, according to the Nan Yue Qing Feng news, Li Chu Yuan, former secretary of the Party Committee and chairman of Guangzhou Pharmaceutical Group Co., Ltd., is suspected of serious disciplinary and legal violations and is currently under disciplinary review and supervision investigation by the Guangdong Provincial Commission for Discipline Inspection and Supervision. It is reported that Guangzhou Pharmaceutical Group is the parent company of Baiyunshan, a listed company on the A-share market, and Li Chu Yuan previously served as chairman of Baiyunshan. On July 22 of this year, Baiyunshan announced that Li Chu Yuan resigned as chairman of the 9th Board of Directors, executive director, and chairman of the Board's Strategic Development and Investment Committee for personal reasons.
